Cleveland Clinic CorAide Blood Pump Circulatory Support Without Anticoagulation

The Cleveland Clinic CorAide left ventricular assist system consists of a permanently implantable centrifugal pump in which the rotating assembly is completely suspended and noncontacting. A series of chronic animal in vivo studies were conducted to evaluate the biologic effects of CorAide circulatory support without the use of anticoagulation therapy. The CorAide pump was implanted in six calves (five calves for 21 to 32 days and one calf for 95 days). The first five calves received intravenous heparin during the early postoperative periods (2–7 days). Heparin administration was then discontinued and no other anticoagulant drugs were used for the duration of the experiments. The last calf did not receive any anticoagulant except for a bolus dose of heparin (200 U/kg) during surgery. Hemodynamics were stable in all six calves, with a mean pump flow of 5.6 ± 1.2 L/min and mean arterial pressure of 100 ± 4 mm Hg. The blood pump surfaces were clean of thrombus in all six calves. Significant findings at autopsy were limited to one case of renal infarction. There was no incidence of mechanical failure, bleeding, or device infection. The CorAide pump can be safely run with minimal or no anticoagulant therapy.

[1]  P. Tillman,et al.  Platelet function and coagulation parameters in sheep during experimental vascular surgery. , 1981, Laboratory animal science.

[2]  S. Boyce,et al.  An anatomically compatible, wearless, reliable, and nonthrombogenic centrifugal blood pump. , 2001, The Annals of thoracic surgery.

[3]  K. Fukamachi,et al.  The CorAide blood pump , 2001 .

[4]  J F Antaki,et al.  HeartMate II left ventricular assist system: from concept to first clinical use. , 2001, The Annals of thoracic surgery.

[5]  P M Portner,et al.  Improved outcomes with an implantable left ventricular assist system: a multicenter study. , 2001, The Annals of thoracic surgery.

[6]  E. Ringelstein,et al.  Cerebral and systemic embolization during left ventricular support with the Novacor N100 device. , 1998, The Annals of thoracic surgery.

[7]  O H Frazier,et al.  Nonthrombogenic, adhesive cellular lining for left ventricular assist devices. , 1998, Circulation.

[8]  R K Jarvik,et al.  Research and development of an implantable, axial-flow left ventricular assist device: the Jarvik 2000 Heart. , 2001, The Annals of thoracic surgery.

[9]  H. Scheld Mechanical Support - Benefits and Risks , 1997, The Thoracic and cardiovascular surgeon.

[10]  K. Fukamachi,et al.  In vivo hemodynamic performance of the Cleveland Clinic CorAide blood pump in calves. , 2001, The Annals of thoracic surgery.

[11]  Scheld Hh Mechanical support--benefits and risks. , 1997 .

[12]  S. Colan,et al.  Evaluation of regional differences in right ventricular systolic function by acoustic quantification echocardiography and cine magnetic resonance imaging. , 1998, Circulation.

[13]  G P Noon,et al.  Clinical experience with the MicroMed DeBakey ventricular assist device. , 2001, The Annals of thoracic surgery.

[14]  N G Smedira,et al.  Factors influencing HLA sensitization in implantable LVAD recipients. , 1997, The Annals of thoracic surgery.

[15]  E Wolner,et al.  Lessons learned from the first clinical implants of the DeBakey ventricular assist device axial pump: a single center report. , 2001, The Annals of thoracic surgery.

[16]  M C Oz,et al.  Low thromboembolic risk without anticoagulation using advanced-design left ventricular assist devices. , 1996, The Annals of thoracic surgery.

[17]  S Westaby,et al.  Reliable long-term non-pulsatile circulatory support without anticoagulation. , 2001, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.